Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity
OBJECTIVES: To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH).METHODS: A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis treatment...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2014-02, Vol.18 (2), p.188-195 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 195 |
|---|---|
| container_issue | 2 |
| container_start_page | 188 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 18 |
| creator | Satyaraddi, A. Velpandian, T. Sharma, S. K. Vishnubhatla, S. Sharma, A. Sirohiwal, A. Makharia, G. K. Sinha, S. Biswas, A. Singh, S. |
| description | OBJECTIVES: To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH).METHODS: A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis
treatment and were prospectively followed for the development of DIH. Plasma drug levels were measured at 0, 1, 2 and 4 h on days 1, 7 and 14 of treatment. Plasma drug levels in 15 patients who developed DIH (cases) were compared with 95 patients who did not (controls).RESULTS: Female
sex, body mass index < 17 kg/m2 and baseline serum albumin < 4 g/dl predicted risk of DIH on univariate analyses. Free and total plasma RMP levels (Cmax and AUC0-4) on days 1, 7 and 14 were significantly higher in cases compared to controls and
predicted development of DIH. Day 7 total RMP Cmax and AUC0-4 were higher in cases (mean 26.73, standard deviation [SD] 5.72 and 47.58, SD 33.10) than in controls (7.87, SD 10.95 and 14.01, SD 10.69, respectively).CONCLUSIONS: Plasma RMP levels were higher in
cases than in controls and independently predicted subsequent development of DIH. The Cmax of Day 7 total RMP level (cut-off 12.50 mg/l) predicted subsequent development of DIH in 93.3% of the patients. |
| doi_str_mv | 10.5588/ijtld.13.0128 |
| format | Article |
| fullrecord | <record><control><sourceid>pubtec_pubme</sourceid><recordid>TN_cdi_pubmed_primary_24429311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2014/00000018/00000002/art00011</ingid><sourcerecordid>iuatld/ijtld/2014/00000018/00000002/art00011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-a04121190e39d70657fe2f1b4db60b7af3e0e2c07c00b266661c3e4eed30df863</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhiMEoqVw5IpyQeoly4ztbJwjWsqHVAkhwdlyHGfrlRMHf7SUX4_d3cIJXzwaPXpm9E5VvUbYtC3n78wh2nGDdANI-JPqHDm2TdcTeJprIF1DO-zPqhchHAAIInbPqzPCGOkp4nkld857bWU0bqndVK9WhlnWcommiWnQXiXrggn16NO-tvpW21DfmXhThzQE_TPpJdZjabt1LnV23OhVRhfdL6NMvH9ZPZukDfrV6b-ofny8-r773Fx__fRl9_66UazH2EhgmNfrQdN-7GDbdpMmEw5sHLYwdHKiGjRR0CmAgWzzQ0U103qkME58Sy-qy6N39S6vFaKYTVDaWrlol4LAlgEhtGU8o80RVd6F4PUkVm9m6e8FgiipiodUBVJRUs38m5M6DbMe_9KPMWbg7QmQQUk7ebkoE_5xnGAGi-jDkTPLPoclxcElv-RUhEmyTDzOJYBMwMNDfiqACOlj6ZRx3_6nUY-mcvtyenGLfCFZSRA4aQWylotRTzLZKKL0Yv9bhOz8A1rqs4Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540223548</pqid></control><display><type>article</type><title>Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Satyaraddi, A. ; Velpandian, T. ; Sharma, S. K. ; Vishnubhatla, S. ; Sharma, A. ; Sirohiwal, A. ; Makharia, G. K. ; Sinha, S. ; Biswas, A. ; Singh, S.</creator><creatorcontrib>Satyaraddi, A. ; Velpandian, T. ; Sharma, S. K. ; Vishnubhatla, S. ; Sharma, A. ; Sirohiwal, A. ; Makharia, G. K. ; Sinha, S. ; Biswas, A. ; Singh, S.</creatorcontrib><description>OBJECTIVES: To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH).METHODS: A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis
treatment and were prospectively followed for the development of DIH. Plasma drug levels were measured at 0, 1, 2 and 4 h on days 1, 7 and 14 of treatment. Plasma drug levels in 15 patients who developed DIH (cases) were compared with 95 patients who did not (controls).RESULTS: Female
sex, body mass index < 17 kg/m2 and baseline serum albumin < 4 g/dl predicted risk of DIH on univariate analyses. Free and total plasma RMP levels (Cmax and AUC0-4) on days 1, 7 and 14 were significantly higher in cases compared to controls and
predicted development of DIH. Day 7 total RMP Cmax and AUC0-4 were higher in cases (mean 26.73, standard deviation [SD] 5.72 and 47.58, SD 33.10) than in controls (7.87, SD 10.95 and 14.01, SD 10.69, respectively).CONCLUSIONS: Plasma RMP levels were higher in
cases than in controls and independently predicted subsequent development of DIH. The Cmax of Day 7 total RMP level (cut-off 12.50 mg/l) predicted subsequent development of DIH in 93.3% of the patients.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.13.0128</identifier><identifier>PMID: 24429311</identifier><language>eng</language><publisher>Paris, France: International Union Against Tuberculosis and Lung Disease</publisher><subject>Adult ; Anti-Tuberculosis Drugs ; Antitubercular Agents - administration & dosage ; Antitubercular Agents - adverse effects ; Antitubercular Agents - blood ; Antitubercular Agents - pharmacokinetics ; Area Under Curve ; Bacterial diseases ; Biological and medical sciences ; Case-Control Studies ; Chemical and Drug Induced Liver Injury - blood ; Chemical and Drug Induced Liver Injury - etiology ; Drug Administration Schedule ; Drug Induced Hepatotoxicity ; Drug Monitoring ; Drug Therapy, Combination ; Female ; Human bacterial diseases ; Humans ; Infectious diseases ; Isoniazid - adverse effects ; Isoniazid - blood ; Male ; Medical sciences ; Metabolic Clearance Rate ; Mycobacterium ; Plasma Drug Levels ; Pneumology ; Prospective Studies ; Pyrazinamide - adverse effects ; Pyrazinamide - blood ; rifampicin ; Rifampin - adverse effects ; Rifampin - blood ; Risk Factors ; Tuberculosis - blood ; Tuberculosis - diagnosis ; Tuberculosis - drug therapy ; Tuberculosis and atypical mycobacterial infections</subject><ispartof>The international journal of tuberculosis and lung disease, 2014-02, Vol.18 (2), p.188-195</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-a04121190e39d70657fe2f1b4db60b7af3e0e2c07c00b266661c3e4eed30df863</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28212938$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24429311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Satyaraddi, A.</creatorcontrib><creatorcontrib>Velpandian, T.</creatorcontrib><creatorcontrib>Sharma, S. K.</creatorcontrib><creatorcontrib>Vishnubhatla, S.</creatorcontrib><creatorcontrib>Sharma, A.</creatorcontrib><creatorcontrib>Sirohiwal, A.</creatorcontrib><creatorcontrib>Makharia, G. K.</creatorcontrib><creatorcontrib>Sinha, S.</creatorcontrib><creatorcontrib>Biswas, A.</creatorcontrib><creatorcontrib>Singh, S.</creatorcontrib><title>Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity</title><title>The international journal of tuberculosis and lung disease</title><addtitle>Int J Tuberc Lung Dis</addtitle><description>OBJECTIVES: To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH).METHODS: A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis
treatment and were prospectively followed for the development of DIH. Plasma drug levels were measured at 0, 1, 2 and 4 h on days 1, 7 and 14 of treatment. Plasma drug levels in 15 patients who developed DIH (cases) were compared with 95 patients who did not (controls).RESULTS: Female
sex, body mass index < 17 kg/m2 and baseline serum albumin < 4 g/dl predicted risk of DIH on univariate analyses. Free and total plasma RMP levels (Cmax and AUC0-4) on days 1, 7 and 14 were significantly higher in cases compared to controls and
predicted development of DIH. Day 7 total RMP Cmax and AUC0-4 were higher in cases (mean 26.73, standard deviation [SD] 5.72 and 47.58, SD 33.10) than in controls (7.87, SD 10.95 and 14.01, SD 10.69, respectively).CONCLUSIONS: Plasma RMP levels were higher in
cases than in controls and independently predicted subsequent development of DIH. The Cmax of Day 7 total RMP level (cut-off 12.50 mg/l) predicted subsequent development of DIH in 93.3% of the patients.</description><subject>Adult</subject><subject>Anti-Tuberculosis Drugs</subject><subject>Antitubercular Agents - administration & dosage</subject><subject>Antitubercular Agents - adverse effects</subject><subject>Antitubercular Agents - blood</subject><subject>Antitubercular Agents - pharmacokinetics</subject><subject>Area Under Curve</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Chemical and Drug Induced Liver Injury - blood</subject><subject>Chemical and Drug Induced Liver Injury - etiology</subject><subject>Drug Administration Schedule</subject><subject>Drug Induced Hepatotoxicity</subject><subject>Drug Monitoring</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Isoniazid - adverse effects</subject><subject>Isoniazid - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Mycobacterium</subject><subject>Plasma Drug Levels</subject><subject>Pneumology</subject><subject>Prospective Studies</subject><subject>Pyrazinamide - adverse effects</subject><subject>Pyrazinamide - blood</subject><subject>rifampicin</subject><subject>Rifampin - adverse effects</subject><subject>Rifampin - blood</subject><subject>Risk Factors</subject><subject>Tuberculosis - blood</subject><subject>Tuberculosis - diagnosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis and atypical mycobacterial infections</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v1DAQhiMEoqVw5IpyQeoly4ztbJwjWsqHVAkhwdlyHGfrlRMHf7SUX4_d3cIJXzwaPXpm9E5VvUbYtC3n78wh2nGDdANI-JPqHDm2TdcTeJprIF1DO-zPqhchHAAIInbPqzPCGOkp4nkld857bWU0bqndVK9WhlnWcommiWnQXiXrggn16NO-tvpW21DfmXhThzQE_TPpJdZjabt1LnV23OhVRhfdL6NMvH9ZPZukDfrV6b-ofny8-r773Fx__fRl9_66UazH2EhgmNfrQdN-7GDbdpMmEw5sHLYwdHKiGjRR0CmAgWzzQ0U103qkME58Sy-qy6N39S6vFaKYTVDaWrlol4LAlgEhtGU8o80RVd6F4PUkVm9m6e8FgiipiodUBVJRUs38m5M6DbMe_9KPMWbg7QmQQUk7ebkoE_5xnGAGi-jDkTPLPoclxcElv-RUhEmyTDzOJYBMwMNDfiqACOlj6ZRx3_6nUY-mcvtyenGLfCFZSRA4aQWylotRTzLZKKL0Yv9bhOz8A1rqs4Y</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Satyaraddi, A.</creator><creator>Velpandian, T.</creator><creator>Sharma, S. K.</creator><creator>Vishnubhatla, S.</creator><creator>Sharma, A.</creator><creator>Sirohiwal, A.</creator><creator>Makharia, G. K.</creator><creator>Sinha, S.</creator><creator>Biswas, A.</creator><creator>Singh, S.</creator><general>International Union Against Tuberculosis and Lung Disease</general><general>International Union against Tuberculosis and Lung Disease</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20140201</creationdate><title>Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity</title><author>Satyaraddi, A. ; Velpandian, T. ; Sharma, S. K. ; Vishnubhatla, S. ; Sharma, A. ; Sirohiwal, A. ; Makharia, G. K. ; Sinha, S. ; Biswas, A. ; Singh, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-a04121190e39d70657fe2f1b4db60b7af3e0e2c07c00b266661c3e4eed30df863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Anti-Tuberculosis Drugs</topic><topic>Antitubercular Agents - administration & dosage</topic><topic>Antitubercular Agents - adverse effects</topic><topic>Antitubercular Agents - blood</topic><topic>Antitubercular Agents - pharmacokinetics</topic><topic>Area Under Curve</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Chemical and Drug Induced Liver Injury - blood</topic><topic>Chemical and Drug Induced Liver Injury - etiology</topic><topic>Drug Administration Schedule</topic><topic>Drug Induced Hepatotoxicity</topic><topic>Drug Monitoring</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Isoniazid - adverse effects</topic><topic>Isoniazid - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Mycobacterium</topic><topic>Plasma Drug Levels</topic><topic>Pneumology</topic><topic>Prospective Studies</topic><topic>Pyrazinamide - adverse effects</topic><topic>Pyrazinamide - blood</topic><topic>rifampicin</topic><topic>Rifampin - adverse effects</topic><topic>Rifampin - blood</topic><topic>Risk Factors</topic><topic>Tuberculosis - blood</topic><topic>Tuberculosis - diagnosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis and atypical mycobacterial infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Satyaraddi, A.</creatorcontrib><creatorcontrib>Velpandian, T.</creatorcontrib><creatorcontrib>Sharma, S. K.</creatorcontrib><creatorcontrib>Vishnubhatla, S.</creatorcontrib><creatorcontrib>Sharma, A.</creatorcontrib><creatorcontrib>Sirohiwal, A.</creatorcontrib><creatorcontrib>Makharia, G. K.</creatorcontrib><creatorcontrib>Sinha, S.</creatorcontrib><creatorcontrib>Biswas, A.</creatorcontrib><creatorcontrib>Singh, S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Satyaraddi, A.</au><au>Velpandian, T.</au><au>Sharma, S. K.</au><au>Vishnubhatla, S.</au><au>Sharma, A.</au><au>Sirohiwal, A.</au><au>Makharia, G. K.</au><au>Sinha, S.</au><au>Biswas, A.</au><au>Singh, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><addtitle>Int J Tuberc Lung Dis</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>18</volume><issue>2</issue><spage>188</spage><epage>195</epage><pages>188-195</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>OBJECTIVES: To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH).METHODS: A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis
treatment and were prospectively followed for the development of DIH. Plasma drug levels were measured at 0, 1, 2 and 4 h on days 1, 7 and 14 of treatment. Plasma drug levels in 15 patients who developed DIH (cases) were compared with 95 patients who did not (controls).RESULTS: Female
sex, body mass index < 17 kg/m2 and baseline serum albumin < 4 g/dl predicted risk of DIH on univariate analyses. Free and total plasma RMP levels (Cmax and AUC0-4) on days 1, 7 and 14 were significantly higher in cases compared to controls and
predicted development of DIH. Day 7 total RMP Cmax and AUC0-4 were higher in cases (mean 26.73, standard deviation [SD] 5.72 and 47.58, SD 33.10) than in controls (7.87, SD 10.95 and 14.01, SD 10.69, respectively).CONCLUSIONS: Plasma RMP levels were higher in
cases than in controls and independently predicted subsequent development of DIH. The Cmax of Day 7 total RMP level (cut-off 12.50 mg/l) predicted subsequent development of DIH in 93.3% of the patients.</abstract><cop>Paris, France</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>24429311</pmid><doi>10.5588/ijtld.13.0128</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2014-02, Vol.18 (2), p.188-195 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_pubmed_primary_24429311 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Anti-Tuberculosis Drugs Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Antitubercular Agents - blood Antitubercular Agents - pharmacokinetics Area Under Curve Bacterial diseases Biological and medical sciences Case-Control Studies Chemical and Drug Induced Liver Injury - blood Chemical and Drug Induced Liver Injury - etiology Drug Administration Schedule Drug Induced Hepatotoxicity Drug Monitoring Drug Therapy, Combination Female Human bacterial diseases Humans Infectious diseases Isoniazid - adverse effects Isoniazid - blood Male Medical sciences Metabolic Clearance Rate Mycobacterium Plasma Drug Levels Pneumology Prospective Studies Pyrazinamide - adverse effects Pyrazinamide - blood rifampicin Rifampin - adverse effects Rifampin - blood Risk Factors Tuberculosis - blood Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis and atypical mycobacterial infections |
| title | Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T08%3A08%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20of%20plasma%20anti-tuberculosis%20drug%20levels%20with%20subsequent%20development%20of%20hepatotoxicity&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Satyaraddi,%20A.&rft.date=2014-02-01&rft.volume=18&rft.issue=2&rft.spage=188&rft.epage=195&rft.pages=188-195&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.13.0128&rft_dat=%3Cpubtec_pubme%3Eiuatld/ijtld/2014/00000018/00000002/art00011%3C/pubtec_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540223548&rft_id=info:pmid/24429311&rft_ingid=iuatld/ijtld/2014/00000018/00000002/art00011&rfr_iscdi=true |